Skip to content

Disorders of Sexual Development and Gonadal Tumor Risk

DEV-GEN-RiTuGo - Assessment of Individual Gonadal Tumor Risk in Patients With Disorders of Sexual Developpment According to the Etiology.

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT06682078
Acronym
DEV-GEN-RiTuGo
Enrollment
80
Registered
2024-11-12
Start date
2023-09-01
Completion date
2024-06-01
Last updated
2025-04-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Disorders of Sexual Development

Keywords

surgery, pediatrics, Urology, Endocrinology, Gonadoblastoma, Dysgerminoma, neoplasms, gonadal tissue, sexual development, oncology, gonadal dysgenesis, androgen-insensitivity syndrome, testicular regression syndrome, anti-mullerian hormone

Brief summary

Disorders of Sexual Development are rare and represent a spectrum of heterogeneous pathologies. The risk of developing a malignant gonadal germ cell tumor (MGCT) exists and varies according to the etiology. The indication for prophylactic gonadectomy must be modulated and discussed for all patients. It is essential to assess each patient's individual risk. The aim of our study is to assess gonadal tumor risk in patients with Disorders of Sexual Development according to etiology The primary objective is to evaluate tumor risk and the indication for gonadectomy in cases of Disorders of Sexual Development according to etiology. The secondary objectives are to evaluate the timing of gonadectomy, to monitor changes in practice over time, and to assess the contribution of imaging and/or biological tests to tumor detection.

Interventions

OTHERNot applicable . Non-interventional retrospective study, only on datas.

Not applicable . Non-interventional retrospective study, only on datas.

Sponsors

Hospices Civils de Lyon
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
RETROSPECTIVE

Eligibility

Sex/Gender
ALL
Healthy volunteers
No

Inclusion criteria

* Patients who underwent gonadectomy for variation in genital development between 1990 and 2022. * Pathological anatomy examination in Lyon * With clinical data * With karyotype * 3 categories: * with genetic diagnosis * without genetic diagnosis because searched but not found * without genetic diagnosis because not searched

Exclusion criteria

* Biopsies without gonadectomy * Fetus * Operated outside the period 1990-2022 * Lack of clinical data * No karyotype

Design outcomes

Primary

MeasureTime frameDescription
Presence or absence of gonadal tumor lesion after gonadectomy, in case of Disorders of sexual development (DSD) according to anatomo-pathological analysis.The outcome measure will be assessed and the datas reported for each patient will be collected, from birth until the study completion date, or by default until the date of death from any cause. Datas will be collected during the 10 months of the studyDatas about the gonadectomy surgical pieces performed between1990 and 2022 are reviewed for the study by Dr Frédérique Dijoud, anatomo-pathologist at the DEV-GEN CRMR in Lyon, to confirm the présence or absence of a gonadal tumor lesion, in order to avoid intra- and inter-reader interpretation bias.

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026